The network graphs in the sources visualize the complex relationships between **pharmacogenomic (PGx) genes**, **prescribed medications**, and their collective impact on **fall or Emergency Department (ED) risks**.  
You can interpret these graphs by understanding the following components:

### 1\. Node Types and Visual Representation

The nodes (the shapes in the graphs) represent different entities involved in the study:

* **Genes (Tier 1):** Represented as **red circles**. These are high-evidence genes often included in CPIC guidelines, such as **CYP3A4, SLCO1B1, and CYP2D6** 1-3.  
* **Genes (Tier 2):** Represented as **orange circles**, such as **HMGCR**, indicating a slightly different level of clinical evidence 1, 3\.  
* **Drugs:** Represented as **light blue diamonds**. These include medications like **SIMVASTATIN, FUROSEMIDE, and CARVEDILOL** 1, 3, 4\.  
* **Phenotypes:** Represented as **light blue squares**, showing outcomes or adverse risk descriptors (e.g., "S Of Adverse") 3, 5\.

### 2\. Edge Meanings (Connections)

The lines (edges) between nodes define the nature of their relationship:

* **feature\_importance\_drug\_gene:** These edges link drugs to genes based on statistical importance in predicting a fall or ED visit. For instance, **FUROSEMIDE** is linked to **ADD1**, and **SIMVASTATIN** is linked to multiple genes like **ABCB1** and **SLCO1B1** 6, 7\.  
* **co\_metabolizes:** Represented by **thicker blue lines** in the topology images, these show genes that work together in metabolic pathways 3, 6, 8\.  
* **metabolizes:** General relationships where a gene is responsible for the metabolism of a drug or substrate 6, 9, 10\.

### 3\. Interpreting Importance and Centrality

* **Feature Importance and Rank:** In the underlying data, each drug is ranked by its predictive power for the specific cohort. For example, in the **falls 65-74** cohort, **FUROSEMIDE** is the \#1 ranked drug feature, whereas **CARVEDILOL** is ranked \#1 for the **ED 65-74** cohort 7, 11\.  
* **Degree:** This refers to how many connections a node has. High-degree genes like **SLCO1B1** (degree of 13\) or **CYP3A5** (degree of 11-13) act as central "hubs" in the network, meaning they interact with a wide variety of medications and other genes 2, 5, 11\.  
* **Weight/Thickness:** The thickness of the lines indicates the strength of the relationship or the level of feature importance. Thicker lines represent more significant statistical or biological associations 3, 6, 7, 12\.

### 4\. Cohort and Contextual Differences

Each graph is specific to a **cohort** (Falls vs. ED), **age band** (65-74 vs. 75-84), and **density bin** 6, 7, 12, 13\.

* **Fall Cohorts:** These networks are often characterized by strong associations with **GABAPENTIN, PREDNISONE, and FUROSEMIDE** 14, 15\.  
* **ED Cohorts:** These networks show a broader medication pattern including **LISINOPRIL, OMEPRAZOLE, and benzodiazepines** alongside some overlap with the fall-risk medications 15\.

By looking at the clusters of red circles (genes) and their connections to blue diamonds (drugs), you can identify which PGx-related pathways are most active or "at risk" for a specific patient population 3, 16\.  
